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pressed in many tissues, particularly epithelial cells of small intestine (SGLT1) (50, 51) and kidney (SGLT1 and SGLT2) (25, 40) . The GLUT family of transporters consists of 14 members, but the most commonly expressed isoforms involved in glucose transport across renal and intestinal epithelia are GLUT1 and GLUT2 (3, 29) .
At the enterocyte brush border membrane (BBM), SGLT1 is a high-affinity, low-capacity transporter that allows active glucose uptake from the intestinal lumen. SGLT1-mediated glucose uptake, in turn, promotes BBM insertion of GLUT2 which provides an additional high-capacity pathway for glucose transport that is crucial to absorb the raised levels of luminal glucose generated at peak carbohydrate digestive activity. Indeed, the transport capability of GLUT2 at the BBM can be up to three times greater than that of SGLT1 (27, 28, 30, 47) . Glucose exits the enterocyte via GLUT2 at the basolateral membrane (BLM).
The rate of intestinal glucose transport is regulated by both systemic and luminal stimuli. Hormones, such as insulin (43, 47) , pancreatic glucagon (15) , GIP (7), GLP-2 (6), and CCK (22) , are some of the established endocrine signals that are known to modulate the rate of enterocyte glucose transport. The level of glucose in blood (11, 12, 39) and intestinal lumen (12) also influences the uptake process. In addition, there is much evidence for the importance of other luminal stimuli in control of intestinal glucose transport. Thus luminal adenosine and cAMP (32) and prostaglandin E 2 (44) stimulate glucose uptake in intact small intestine. Recent interest has focused on the inhibitory action of leptin. This peptide hormone is secreted into the gastric lumen and passes to the small intestine where, after binding to its receptor at the jejunal BBM (1), it rapidly inhibits SGLT1-mediated glucose transport (18) . We have provided evidence that luminal angiotensin II (AII) is also a negative regulator of intestinal glucose transport. We reported that jejunal enterocytes express a renin-angiotensin system (RAS) and that addition of the RAS product, AII, to mucosal fluid rapidly (within minutes) blocks SGLT1-mediated glucose uptake, acting via AT 1 receptors located at the BBM (49) .
Streptozotocin-induced diabetes mellitus promotes glucose transport across the rat intestinal BBM (4, 14, 23) and this is a likely consequence of increased BBM expression of both SGLT1 and GLUT2 (14, 16, 28) . However, the triggers for increased glucose transport remain largely unexplored. Studies have shown that renal proximal tubule cells are able to synthesize and secrete AII into the luminal fluid and that AII might regulate SGLT-mediated transport in these cells (41) . Interestingly, exposure of proximal tubule cells to 25 mM glucose (a similar level to that seen in plasma of streptozotocin-diabetic animals) evoked a reduced AII binding to these cells (42) .
In light of these findings, we have studied the potential involvement of the enterocyte RAS in the increased intestinal glucose uptake induced by diabetes. We first examined the effects of streptozotocin-induced diabetes in rats on expression of the enterocyte RAS. Second, we compared the effects of addition of AII to mucosal fluid on SGLT1 and GLUT2-mediated uptake by everted jejunum from normal and diabetic animals.
MATERIALS AND METHODS

Animals.
The study used adult male Wister rats (280 -320 g) purchased from the Laboratory Animal Services Centre at the Chinese University of Hong Kong. All procedures were approved by the Animal Ethical Committee of the Chinese University of Hong Kong. Experimental type I diabetes was chemically induced by a single intravenous injection of streptozotocin (80 mg/kg) and used up to 3 wk later. Control animals were injected with vehicle (0.1 M citrate buffer, pH 4.5). Animals were maintained on food (LAB DIET, USA, PROLAB RMH 2500, 5P14) and water ad libitum up to the time of experimentation. Only those diabetic rats with blood glucose above 20 mM were used for the study. Anesthesia before removal of the intestine was achieved with pentobarbital (50 mg/kg ip). BBM vesicles and enterocytes were prepared from 20-cm-long segments of jejunum beginning 10 cm distal to the ligament of Treitz. Intestinal segments 3-4 cm in length, taken from the midpoint of these regions, were used for uptake experiments (49) .
Isolation of enterocytes. Villus cells were harvested by a Ca 2ϩ -chelation technique (17, 46) , a procedure that produces enterocytes with a high viability. Briefly, isolated intestinal segments were flushed through with ice-cold saline followed by air. The segment was tied off at one end and filled with Ca 2ϩ -free hypertonic isolation buffer (7 mM K2SO4, 44 mM K2HPO4, 9 mM NaHCO3, 10 mM HEPES, 2 mM L-glutamine, 0.5 mM dithiothreitol, 1 mM Na2EDTA, and 180 mM glucose, pH 7.4), equilibrated with 95% O2-5% CO2, avoiding overdistention. The segment was then tied off to form a closed sac and incubated in 0.9% saline at 37°C with gentle shaking for 16 min. Cells were dislodged manually, and the resulting suspension was collected and centrifuged for 30 s at 500 g. The pellet was resuspended in freshly prepared cold buffer and recentrifuged, a procedure that was repeated twice. RNase Out (Gibco, Invitrogen) RNase inhibitor was added to all solutions used for enterocyte RNA isolation.
BBM preparation. The methods used to prepare BBM vesicles have been described previously (31) . All procedures were carried out at 4°C. Isolated jejunal segments from control or diabetic rats were rinsed with cold saline and everted over a glass rod. The tissue was securely tied to the end of the rod and preincubated in gassed (95% O 2-5% CO2) bicarbonate buffer (in mM: 128 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, and 20 NaHCO3) for 6 min at 37°C. The segment was then incubated for 2 min in a fresh buffer containing 50 mM D-glucose, then quickly transferred to a large beaker containing ice-cold saline and stirred at high speed for 1 min. The segment was placed on an ice-cold glass plate, and the mucosa was scraped away. Mucosal scrapings were added to homogenization buffer [50 mM mannitol, 2 mM HEPES, 0.25 mM phenylmethylsulfonyl fluoride (PMSF), pH 7.1, and 28 ml/g mucosa].
The mixture was homogenized three times at 50% maximum speed for 20 s using an Ultra Turrax homogenizer (Janke and Kunkel). MgCl 2 was added to a final concentration of 10 mM, and the mixture was stirred on ice for 20 min and then centrifuged at 3,000 g for 15 min. The supernatant was recentrifuged at 27,000 g for 30 min. The pellet was resuspended in buffer (100 mM mannitol, 0.1 mM MgSO4, and 0.4 mM HEPES-Tris, pH 7.2) and centrifuged for 15 min at 6,000 g. The supernatant was then recentrifuged at 27,000 g for 30 min. The resulting pellet was suspended in the final buffer (300 mM mannitol, 10 mM HEPES-Tris, 0.1 mM MgSO4, and 0.25 mM PMSF, pH 7.4) by being passed 6 times through a 25-gauge needle. The purified BBM pellet was then resuspended in the final buffer at a protein concentration of 3-6 mg/ml.
Real-time PCR analysis. Quantitative RT-PCR was performed using an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA) as described previously (9) . Briefly, total RNA was extracted from freshly prepared enterocytes using TRIzol reagent (Gibco, Invitrogen) according to the manufacturer's instructions. RNase Out was added to the RNA solutions to prevent degradation by RNase. Total RNA served as the template for cDNA preparation using the Bio-Rad One-Step cDNA preparation kit. Primers were designed from rat cDNA sequences using Primer Express Software purchased from Applied Biosystems (Perkin-Elmer). ␤-Actin was used as a reference gene to normalize the relative expression of each RAS gene. The sequences of primers used are shown in Table 1 .
Syber Green reactions were set up in a volume of 25 l with ABI two-step Syber Green PCR reagents. Each reaction consisted of 12.5 l PCR master mix, 0.05-0.30 M of each amplification primer, and 1 l cDNA. Each sample was run in duplicate with an initial 10-min period at 95°C to enable the reaction, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. The samples were heated to 60°C for 1 min, then to 95°C over the next minute, and finally cooled slowly from 95°C to 60°C over 20 min to collect data for the analysis of dissociation curve. Amplification data were collected by the 7700 Sequence Detector and analyzed with Sequence Detection System software. The RNA concentration in each sample was determined from the threshold cycle (CT) at which fluorescence was first detected, the cycle number being inversely related to RNA concentration. The fold changes in mRNA expression were calculated using the 2 Ϫ⌬⌬CT method (35) .
Western blot analysis. The methods used for immunoblotting have been described previously (24) . Protein from BBM vesicles or enterocyte homogenate was extracted using the CytoBuster Protein Extraction Reagent (Novagen, Darmstadt, Germany). Protein content was determined by Bradford protein assay kit (Bio-Rad, Munich, Germany). Proteins (10 g/lane) were subjected to electrophoresis on a 10% (wt/vol) polyacrylamide gel. The blotted protein was saturated by submersion in 5% (wt/vol) nonfat skimmed milk in PBS (pH 7.4) with 0.1% (vol/vol) Tween 20 for 1 h at room temperature. The membranes were sequentially and individually incubated with anti-AT 1 receptor rabbit polyclonal antibodies (Santa Cruz Biotechnology) Table 1 .
Sequences of specific primers for the RAS components and ␤-actin used for real-time quantitative RT-PCR
Gene
Forward Primer Reverse Primer
RAS, renin-angiotensin system; AO, angiotensinogen; AT1 and AT2, angiotensin II type 1 and type 2, respectively; ACE, angiotensin-converting enzyme.
(1:200), anti-AT2 receptor goat polyclonal antibodies (Santa Cruz Biotechnology) (1:300), antiangiotensinogen rabbit polyclonal antibodies (1:20,000), antiangiotensin-converting enzyme (ACE) goat polyclonal antibodies (Santa Cruz Biotechnology) (1:1,300), antirenin goat polyclonal antibodies (Santa Cruz Biotechnology) (1:200), anti-SGLT1 rabbit polyclonal antibodies (Abcam) (1:600), anti-GLUT2 goat polyclonal antibodies (Santa Cruz Biotechnology) (1:1,300), anti-␤-actin mouse polyclonal antibodies (Chemicon) (1:2,500), antialkaline phosphatase mouse monoclonal antibodies (Developmental Studies Hybridoma Bank) (1:200), and anti-Na ϩ -K ϩ -ATPase rabbit polyclonal antibody (Santa Cruz Biotechnology) (1:200) overnight at 4°C. After being rinsed in PBS, the membranes were incubated with the following corresponding peroxidase-labeled secondary antibodies for 1 h at room temperature: anti-rabbit IgG antibody (Amersham) (1:1,300), anti-goat IgG antibody (1:1,500) (Amersham), and antimouse IgG antibody (Amersham) (1:2,500). The positive signal was revealed using enhanced chemiluminescence plus Western blotting detection reagent and autoradiography film (Amersham). The intensity of the bands was quantified using FluorChem software.
Immunohistochemistry. Immunofluorescent labeling was used to determine the mucosal localization of AT 1 receptors, AT2 receptors, and ACE as described previously (49), with some modifications. Isolated jejunal segments were rinsed with cold saline containing aprotinin (Trasylol; 5,000 kallikrein inactivator units/ml) and complete protease inhibitor (GE Healthcare) (1 pellet/500 ml saline) and everted over a glass rod. The tissue was securely tied to the end of the rod and preincubated in gassed (95% O2-5% CO2) bicarbonate buffer (in mM: 128 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, and 20 NaHCO3) for 6 min at 37°C. Tissue was transferred to fresh buffer containing 50 mM D-glucose and incubated for 2 min. The tissue was then quickly put into ice-cold 4% paraformaldehyde in 0.1 M PBS (pH 7.4) and incubated at 4°C overnight. Tissue segments were rinsed with PBS and incubated with 20% sucrose in PBS 4°C overnight and embedded in OCT medium (Tissue-Tek). Sections 6 m thick were collected on SuperFrost slides (Menzel-Glaser). Slides were boiled in 10 mM citrate buffer for 10 min to retrieve the antigens. Sections were incubated with 1% BSA and 6% (wt/vol) normal donkey serum (NDS) (Jackson ImmunoResearch) for 1 h at room temperature to block nonspecific antibody binding. Excess blocking solution was poured off, and the slides were incubated overnight at 4°C with primary antibody [anti-AT1 receptor rabbit polyclonal antibodies (Santa Cruz Biotechnology) (1:50), or anti-AT2 receptor rabbit polyclonal antibodies (Santa Cruz Biotechnology) (1:50), or anti-ACE goat polyclonal antibodies (Santa Cruz Biotechnology) (1:50), or anti-GLUT2 rabbit polyclonal antibodies (Santa Cruz Biotechnology) (1:50)] diluted in PBS with 2% normal goat serum and 0.1% Triton X-100. After three washes with PBS, bound primary antibodies were detected by incubating with their corresponding secondary antibodies labeled with Cyc-3 (Jackson ImmunoResearch) (1:100, diluted with 0.1 M PBS containing 2% NDS) at room temperature for 1 h. Immunoreactivity was captured with a fluorescent microscope equipped with a DC480 digital camera (Leica Microsystems).
D-glucose uptake. Mucosal glucose uptake was measured using everted sleeves of jejunum (26) . This procedure has been fully validated, including the concentration dependency of glucose uptake, which showed saturation of the uptake process at 50 mM glucose. In brief, isolated jejunal segments were rinsed with cold saline and everted over a glass rod. The tissue was securely tied to the end of the rod and preincubated in gassed (95% O2-5% CO2) bicarbonate buffer (in mM: 128 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, and 20 NaHCO3) for 2 min at 37°C followed by 4 min in the same buffer to which AII (0.1-5 M; Bachem) or the nonpeptide AII analog L-162313 (100 nM; Sigma-Aldrich) was added. L-162313 was dissolved in 0.01% DMSO and further diluted by saline. The tissue was transferred to fresh buffer containing 50 mM D-glucose and [
14 C]-Dglucose (0.2 Ci/ml) (GE Healthcare) with trace amounts of [ 3 H]-Lglucose (0.1 Ci/ml) (Sigma-Aldrich) to correct for nonspecific uptake. In some experiments the AT 1 receptor antagonist losartan (1 M; Merck) or 0.3 mM phlorizin (Sigma-Aldrich) or 0.1 mM phloretin (Sigma-Aldrich) was added to the buffer. After 2 min, the segments were quickly transferred to ice-cold saline and were stirred at 1,200 rpm for 1 min. The tissue was removed from the rod, oven-dried, and weighed. The dried residue was dissolved by incubation with Soluene-350 (Perkin-Elmer) per 50 mg of tissue at 60°C for 4 h. After the tissue solution had cooled to room temperature, scintillation fluid (Ultima Gold, Perkin-Elmer) was added. Glucose uptake was calculated as pmol ⅐ mg dry wt intestine Ϫ1 ⅐ s Ϫ1 . Statistical analysis. All results were analyzed by Prism 3.0 software. The data are expressed as means Ϯ SE. Student's unpaired two-tailed t-test and one-way analysis of variance were used to detect significant differences between two groups and three or more groups, respectively. For all comparisons, P Ͻ 0.05 was considered statistically significant. For RT-PCR, the C T value of the target gene of a sample was first corrected for the CT value of ␤-actin, before being statistically analyzed (35) .
RESULTS
Diabetes and blood glucose. Treatment with streptozotocin caused an approximate fivefold increase in blood glucose concentration. Blood glucose levels of animals 1, 2, and 3 wk after streptozotocin treatment were not significantly different from each other. The average values for blood glucose in the combined 1-, 2-, and 3-wk control and diabetic groups were 5.4 Ϯ 0.22 and 24.8 Ϯ 1.28 mM, respectively (n ϭ 15, P Ͻ 0.001).
Gene expression of RAS components. The real-time RT-PCR analysis of mRNA expression of AT 1 receptor, AT 2 receptor, angiotensinogen (AO), and ACE normalized to ␤-actin from the jejunum and ileum is shown in Table 2 . Enterocyte mRNA expression of AT 1 , AT 2 , and ACE in diabetic enterocytes was 65%, 77%, and 51%, respectively, of the corresponding control values (P Ͻ 0.01 in all cases). In contrast, expression of AO Values are means Ϯ SE (n ϭ 6). Real-time RT-PCR was used for quantification of mRNA. CT, threshold cycle; NA, nonapplicable; i.e., mRNA expression of renin could not be detected.
a Average of the CT data for each sample.
b ⌬CT value was calculated by the subtraction of the ␤-actin CT from each sample CT.
c ⌬⌬CT value was calculated by subtraction of the control ⌬CT from each transplanted sample ⌬CT.
d Expression relative to jejunum was calculated using the equation 2
Ϫ⌬⌬CT . e CT ϭ 40; i.e., no expression of renin mRNA was detected. mRNA in diabetic jejunum was 44% higher than control jejunum (P Ͻ 0.01). Renin mRNA was undetectable in control and diabetic enterocytes.
Western blot analysis. Western blotting of enterocyte protein revealed the presence of AT 1 and AT 2 receptors, AO, and ACE proteins in both control jejunum and diabetic jejunum (Fig. 1) . Levels of AT 1 and AT 2 receptors and ACE protein in diabetic enterocytes were reduced by some 60%, 70%, and 80%, respectively, compared with the corresponding control (Fig. 1,  A-C) . In contrast, expression of AO in diabetic jejunum was almost 50% higher than its control (Fig. 1D) . Consistent with mRNA determinations, renin protein was not detected in either group (data not shown). SGLT1 protein were detected in BBM in both diabetic and control groups. Expression of SGLT1 protein in the diabetic BBM was 25% higher than that seen in control BBM (Fig. 2A) . Relatively less GLUT2 was detected in control BBM compared with diabetic BBM; diabetes evoked a 135% increase in expression of this transporter (Fig. 2B) . Western blots of protein revealed an approximate 14-fold enrichment of BBM purity, as assessed by alkaline phosphatase activity, compared with enterocyte homogenates from which vesicles were derived, in both control and diabetic animals (Fig. 2, C and D) .
Villus localization of RAS components and GLUT2. Immunocytochemistry revealed the presence of AT 1 receptors, AT 2 receptors, and ACE along the entire villus length at the brush border membrane of both control and diabetic jejunum. BBM expression of AT 1 , AT 2 , and ACE was lower in diabetic jejunum (Fig. 3, B, D, and F, respectively) compared with control jejunum (Fig. 3, A, C , and E, respectively) while GLUT2 expression at the BBM was higher in diabetic compared with control jejunum (Fig. 3, H and G, respectively) . Furthermore, higher magnification showed that GLUT2 immunoreactivity at the BLM of diabetic jejunum was less intense than that seen in control jejunum (Fig. 3, J and I, respectively) . Negative controls of AT 1 receptor, AT 2 receptor, ACE, and GLUT2 immunolabeling experiments in which no primary antibodies were added, respectively, are shown in Fig. 3, K-N .
Effects of diabetes on jejunal glucose uptake and villus length. Mucosal glucose accumulation was promoted by 43% and 58% at 1 wk and 2 wk, respectively, after streptozotocin Fig. 1 . Effects of diabetes on protein expression of angiotensin II (AII) type 1 (AT1) receptor (A), AII type 2 (AT2) receptor (B), angiotensin-converting enzyme (ACE; C), and angiotensinogen (AO; D) in isolated jejunal enterocytes. Protein abundance was determined by Western blotting of enterocyte homogenates. Enterocytes were harvested 2 wk after treatment of rats with citrate buffer (controls) or streptozotocin (STZ; diabetic). Expression was calculated as the optical density of the renin-angiotensin system (RAS) protein compared with respective ␤-actin bands, and diabetic values are expressed relative to control values. Results are given as means Ϯ SE; n ϭ 5. *P Ͻ 0.05, ***P Ͻ 0.001 vs. control. treatment (Fig. 4) . A 3-wk diabetic period did not further enhance glucose uptake compared with 2 wk, and therefore all further studies were carried out using 2-wk diabetic animals. Villus length was measured as the distance from villus base to tip. Diabetes of 2-wk duration caused a 30% increase in villus length (control, 314.5 Ϯ 10.5 m; diabetes, 417.0 Ϯ 5.3 m; P Ͻ 0.05, n ϭ 6 villi/group).
Effects of AII and L-162313 on glucose uptake. The addition of AII (1 and 100 nM) to mucosal fluid bathing diabetic jejunum was without effect on glucose uptake (Fig. 5A) . However, 1 M AII significantly reduced glucose uptake. At the maximum concentration of AII used (5 M), glucose uptake was inhibited by 18%. L-162313 also decreased glucose uptake, the inhibition becoming significant at 10 nM L-162313 (Fig. 5B) . At the maximum concentration of L-162313 used (1 M), glucose uptake was decreased by about 30%. The potency of L-162313 on glucose uptake was therefore clearly greater than AII.
Linear regression was used to estimate the half-maximal inhibitory concentration (IC 50 ) of AII (data not shown). IC 50 represents the effectiveness of AII in inhibiting jejunal glucose uptake. IC 50 for the inhibitory action of AII on jejunal glucose uptake was found to be 631 nM. i.e., 631 nM of AII will inhibit jejunal glucose uptake by 10% (the maximal inhibitory effects of AII on the glucose uptake is about 20%). Using this approach, the IC 50 value for the inhibitory action of L-162313 on glucose uptake was derived from the linear region of dose/inhibitory response relationship. Data showed that only ϳ10 nM of L-162313 was equivalent to the inhibitory effects of IC 50 of AII. It can therefore be concluded that the potency of L-162313 is ϳ63 times greater than AII. On the other hand, mucosal addition of 1 M losartan, an AT 1 receptor antagonist, attenuated the inhibitory action of 5 M AII on glucose uptake (Fig. 6) .
Effects of phlorizin and phloretin on glucose uptake. The presence of phlorizin (0.3 mM) alone in mucosal fluid inhibited glucose uptake by some 65% (Fig. 7 , P Ͻ 0.001) while mucosal phloretin (0.1 mM) alone blocked glucose uptake by 39% (Fig. 7 , P Ͻ 0.05). Thus glucose uptake could be fully accounted for by phlorizin and phloretin-sensitive transport components representing SGLT1-and GLUT2-mediated uptake, respectively. The presence of 5 M AII did not further reduce the lowered glucose uptake induced by phlorizin but induced an additional 24% inhibition of glucose uptake to that seen in presence of phloretin (Fig. 7, P Ͻ 0.05) . GLUT2; B) . Also shown is the ratio of the expression of alkaline phosphatase (AP) and Na ϩ -K ϩ -ATPase in brush border membrane (BBM) prepared from jejunal mucosa from citrate buffer injected (C) and 2-wk diabetic (D) rats. Protein expression in A and B was calculated as the optical density of sample bands compared with the respective ␤-actin band. Diabetic values are expressed relative to control values. Expression in C and D is the ratio of optical density of the alkaline phosphatase bands compared with the respective Na ϩ -K ϩ -ATPase band of the homogenate from which BBM were prepared. Results are given as means Ϯ SE; n ϭ 5. *P Ͻ 0.05.
DISCUSSION
Intestinal glucose transport is known to be controlled by luminal and circulatory factors as described in the introduction, but the possibility for local control of the uptake process has received much less attention. We have recently suggested that intestinal enterocytes should be added to the growing list of cell types that express a RAS and that the enterocyte RAS may therefore provide an autocrine regulation of glucose transport (49). Our suggestion was based on the observations that AO, ACE, and AT 1 and AT 2 receptors were expressed in isolated villus cells, and that addition of the RAS product, AII, to mucosal buffer rapidly inhibited glucose uptake into isolated rat jejunum. The suppressive effect of AII occurred at low concentrations (Ͼ1 nM), was phlorizin sensitive, i.e., acted on SGLT1-mediated transport at the BBM, and was abolished when the AT 1 receptor antagonist losartan was also added to the mucosal fluid.
The stimulatory action of streptozotocin-induced diabetes mellitus on intestinal glucose transport is well documented (11, 14) and is due to both increased sodium-dependent [SGLTmediated transport (13, 14, 16, 23) ] and enhanced GLUT2 transporter expression at the BBM (21, 27, 28, 45) . As shown in Fig. 3, I and J, diabetes strongly upregulated BBM GLUT2 and diminished BLM GLUT2. These findings have parallels with the data of Tobin et al. (47) , who showed that the feeding of a high-fructose or a high-fat diet to mice resulted in increased expression of GLUT2 at the BBM but decreased GLUT2 expression at the BLM. To our knowledge, our finding that diabetes reduces expression of GLUT2 at the enterocyte BLM has not previously been documented. These findings are consistent with others that large amount of apical GLUT2 in diabetic or insulin-resistant states is effectively permanent (8, 10, 29) . This reduced GLUT2 expression implies an additional pathway for glucose exit at the BLM. In this context, it has been reported that streptozotocin-induced diabetes in rats caused a four-to fivefold increased expression of GLUT1 at the BLM (3).
Our present finding of a proportionately higher BBM abundance of GLUT2 compared with SGLT1 in diabetes (Fig. 2, A  and B) , although important, might not result in predominantly GLUT2-mediated glucose uptake at the BBM in this condition since both hyperglycemia (14) and increased luminal glucose level (27) promote the electrochemical driving force for SGLT1-mediated uptake as well as the abundance of SGLT1 protein per se. A raised capacity for total transporter-mediated glucose transport at the cellular level in diabetes is compounded by villus elongation implying an increased population of enterocytes, as well as altered dynamics of enterocyte turnover and maturation during transit of these cells from crypt to villus tip (16) .
The precise extracellular trigger for increased BBM glucose transport in diabetes is unknown, but studies have suggested that raised luminal and/or plasma levels of hormones play a role in regulating glucose transporter expression. Of particular interest is the demonstration that luminal leptin rapidly blocks SGLT1-mediated intestinal glucose absorption, an effect that may involve a PKC-dependent decrease in recruitment of cytosolic SGLT1 protein into the BBM (18) .
Our data show that experimental diabetes reduces expression of AT 1 and AT 2 receptors and ACE in isolated enterocytes. The anomalous finding of enhanced expression of AO in diabetic enterocytes might be explained by downregulation of ACE expression since less AO would be converted to angiotensin peptides. Surprisingly, we were unable to detect renin expression in either control or diabetic enterocytes, implying that, in these cells, AII is generated by a renin-independent biosynthetic pathway. A number of other angiotensin-generating enzymes (e.g., chymase and ACE2) have been shown to be involved in the generation and metabolism of active angiotensin peptides, thus resulting in a complete (i.e., renin and ACE dependent) or incomplete (renin independent) RAS in a diverse array of tissues and organs (36) . Among them, a local and functional RAS with complete RAS components (38) and a local RAS with a renin-independent pathway (34, 37) have been identified in the pancreas and carotid body, respectively. These observations make it plausible that a local RAS without renin is involved in enterocyte AII production (49) .
It is possible that reduced RAS expression might contribute to the elevated jejunal glucose transport in diabetes, the marked inhibitory action of AII that is evident in nondiabetic enterocytes (49) being moderated in diabetic intestine. This would represent the first evidence for involvement of an autocrine mechanism for control of intestinal glucose transport during diabetes. Therefore, it would be of interest to examine how the enterocyte RAS system might interact with other postulated extracellular triggers of increased SGLT1-mediated glucose transport in diabetes, for example, hyperglucagonemia (13) , and whether, like glucagon, the response to AII involves alterations in cellular levels of cAMP. Interestingly, renal proximal tubule cells that have an almost identical process for glucose uptake to that in enterocytes are also able to synthesize and secrete AII (41) . Furthermore, AII has been implicated in the enhanced SGLT-mediated transport in cultured proximal tubule cells (19) induced by cell exposure to high levels of glucose (42) .
Mucosal AII caused a dose-dependent inhibition of glucose uptake in diabetic jejunum which, as has been noted in normal jejunum (49) , was blocked by losartan, implying mediation by AT 1 receptors. However, the suppressive effect of AII on glucose uptake by diabetic jejunum was observed only at high levels of the peptide (above 1 M) which contrasts with the response using jejunum from nondiabetic animals where an AII concentration of 1 nM blocked glucose uptake by 60% (49) . A likely explanation for the relative insensitivity of glucose uptake to AII in diabetes arises from our observation of a disproportionate increase in GLUT2, compared with SGLT1, expression at the diabetic BBM (Fig. 2) . This is consistent with the observation that phlorizin, which blocks SGLT1-dependent uptake but not GLUT2-mediated transport, inhibited glucose uptake in diabetic jejunum by some 65%, which compares with an approximate 95% inhibition of glucose uptake by phlorizin in normal jejunum (49) . The reduction in glucose uptake induced by phloretin, an inhibitor of GLUT-mediated transport, was further reduced by AII. The raised AII-insensitive BBM expression of GLUT2 in diabetes therefore has the effect of moderating the inhibitory action of AII on total glucose uptake.
It is possible that the lower potency of AII in diabetes might be due to the nonaddition of protease inhibitors to mucosal buffer used for uptake experiments, i.e., relatively high levels of AII might be needed to compensate for degradation of the peptide by enzymes released from the epithelium. Interestingly, L-162313, a nonpeptide AT 1 receptor agonist (33, 48) , was a more effective blocker of glucose uptake than AII. However, the percentage inhibition of glucose uptake evoked by L-162313 remained less than the action of AII previously noted in nondiabetic intestine.
In conclusion, we have shown that diabetes downregulates RAS expression in jejunal enterocytes and upregulates SGLT1-and GLUT2-mediated glucose uptake at the BBM. Downregulation of RAS expression in diabetes will serve to reduce the inhibitory action of AII on SGLT1-mediated glucose uptake. Our data have implications for understanding the control of SGLT1-mediated glucose uptake in diabetes. Reduced RAS expression provides an explanation for the decreased effectiveness of AII in blocking SGLT1-mediated glucose uptake in diabetic, compared with control, small intestine since production of AII and its binding to AT 1 receptors at the BBM are downregulated in diabetes. Since the rate of intestinal glucose transport affects insulin release and therefore glycogenic control, our work raises the issue of whether the enterocyte RAS may be a potential therapeutic target to reduce glucose transport in clinical diabetes. The higher potency of L-162313, compared with AII, on BBM glucose transport makes it possible that nonpeptide AT 1 receptor agonists may be used as gut-directed treatment to reduce postprandial hyperglycemia in diabetic patients. and maintained by the Department of Biological Sciences at the University of Iowa (Iowa City, IA). Losartan was generously provided by Merck (Whitehouse Station, NJ).
